Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Non-cash Items (2016 - 2017)

Historic Non-cash Items for Agios Pharmaceuticals (AGIO) over the last 6 years, with Q1 2017 value amounting to $2.9 million.

  • Agios Pharmaceuticals' Non-cash Items rose 2726.98% to $2.9 million in Q1 2017 from the same period last year, while for Mar 2017 it was $2.9 million, marking a year-over-year increase of 2726.98%. This contributed to the annual value of $63.6 million for FY2016, which is 290386.83% up from last year.
  • Latest data reveals that Agios Pharmaceuticals reported Non-cash Items of $2.9 million as of Q1 2017, which was up 2726.98% from $63.6 million recorded in Q4 2016.
  • In the past 5 years, Agios Pharmaceuticals' Non-cash Items registered a high of $360.9 million during Q4 2014, and its lowest value of $1.7 million during Q1 2015.
  • For the 5-year period, Agios Pharmaceuticals' Non-cash Items averaged around $53.7 million, with its median value being $2.4 million (2016).
  • Its Non-cash Items has fluctuated over the past 5 years, first skyrocketed by 808327.19% in 2014, then plummeted by 9895.89% in 2015.
  • Quarter analysis of 5 years shows Agios Pharmaceuticals' Non-cash Items stood at $76.2 million in 2013, then skyrocketed by 373.74% to $360.9 million in 2014, then tumbled by 57.45% to $153.6 million in 2015, then crashed by 58.61% to $63.6 million in 2016, then tumbled by 95.42% to $2.9 million in 2017.
  • Its Non-cash Items stands at $2.9 million for Q1 2017, versus $63.6 million for Q4 2016 and $2.6 million for Q3 2016.